Literature DB >> 12371935

Rejection of porcine islet xenografts mediated by CD4+ T cells activated through the indirect antigen recognition pathway.

Barbara J Olack1, Andrés Jaramillo, Nicholas D Benshoff, Zahid Kaleem, Carol J Swanson, Jeffrey A Lowell, T Mohanakumar.   

Abstract

We have previously demonstrated that human T cells responding to porcine islets are primarily CD4+ and recognized porcine major histocompatibility complex class I molecules through the indirect pathway of antigen presentation. To determine whether this mechanism is responsible for rejection of adult porcine islets xenografts, porcine islets from adult pigs were transplanted under the kidney capsule of streptozotocin-treated CD4-knockout (KO), CD8-KO, Ig-KO and normal C57BL/6 mice. Islet xenografts were acutely rejected with similar kinetics when transplanted into normal C57BL/6 (MST=17.6 +/- 3.5 days) and Ig-KO (MST=19.0 +/- 1.7 days) mice. Interestingly, islet xenografts were rejected significantly earlier when transplanted into CD8-KO mice as compared with normal C57BL/6 (MST=7.0 +/- 0.01 days, P=2 x 10-4). Histopathological analysis revealed classical acute cellular rejection with severe diffuse interstitial cellular infiltrates in all rejected islet xenografts. In contrast, islet xenografts were not rejected when transplanted into CD4-KO mice (MST >/= 100 days, P=1 x 10-9). Histopathological analysis revealed no cellular infiltrates and intact islet xenografts. CD4+ T cells from both normal C57BL/6 and CD8-KO xenograft recipients showed detectable proliferative responses to porcine islets in the presence but not in the absence of syngeneic antigen-presenting cells. In addition, the anti-islet proliferative responses observed in normal C57BL/6 mice were significantly lower than those observed in CD8-KO mice. IgG anti-porcine antibodies were readily detected in C57BL/6 and CD8-KO xenograft recipients but not in Ig-KO or CD4-KO recipients. These results indicate that indirectly activated CD4+ T cells mediate acute rejection of adult porcine islet xenografts and that xenoreactive CD8+ T cells and antibodies are not necessary in this process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12371935     DOI: 10.1034/j.1399-3089.2002.01070.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  7 in total

Review 1.  Transplantation of xenogeneic islets: are we there yet?

Authors:  Philip J O'Connell; Peter J Cowan; Wayne J Hawthorne; Shounan Yi; Andrew M Lew
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

2.  Local co-delivery of pancreatic islets and liposomal clodronate using injectable hydrogel to prevent acute immune reactions in a type 1 diabetes.

Authors:  Muhammad R Haque; Dong Yun Lee; Cheol-Hee Ahn; Jee-Heon Jeong; Youngro Byun
Journal:  Pharm Res       Date:  2014-03-15       Impact factor: 4.200

3.  CD4 T cells mediate cardiac xenograft rejection via host MHC Class II.

Authors:  Robert J Plenter; Todd J Grazia; An N Doan; Ronald G Gill; Biagio A Pietra
Journal:  J Heart Lung Transplant       Date:  2012-07-11       Impact factor: 10.247

Review 4.  Pancreatic islet xenotransplantation: barriers and prospects.

Authors:  Gina R Rayat; Ronald G Gill
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

Review 5.  Pig-islet xenotransplantation: recent progress and current perspectives.

Authors:  Hai-Tao Zhu; Wan-Li Wang; Liang Yu; Bo Wang
Journal:  Front Surg       Date:  2014-03-24

Review 6.  Cellular Immune Responses in Islet Xenograft Rejection.

Authors:  Min Hu; Wayne J Hawthorne; Shounan Yi; Philip J O'Connell
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

7.  Neonatal Pig Sertoli Cells Survive Xenotransplantation by Creating an Immune Modulatory Environment Involving CD4 and CD8 Regulatory T Cells.

Authors:  Gurvinder Kaur; Kandis Wright; Payal Mital; Taylor Hibler; Jonathan M Miranda; Lea Ann Thompson; Katelyn Halley; Jannette M Dufour
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.